Research Papers: Immunology:

Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer

Hitomi Yamashita, Kentaro Nakayama _, Masako Ishikawa, Kohei Nakamura, Tomoka Ishibashi, Kaori Sanuki, Ruriko Ono, Hiroki Sasamori, Toshiko Minamoto, Kouji Iida, Razia Sultana, Noriyoshi Ishikawa and Satoru Kyo

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:5652-5664. https://doi.org/10.18632/oncotarget.23790

Metrics: PDF 2790 views  |   HTML 4630 views  |   ?  


Hitomi Yamashita1, Kentaro Nakayama1, Masako Ishikawa1, Kohei Nakamura1, Tomoka Ishibashi1, Kaori Sanuki1, Ruriko Ono1, Hiroki Sasamori1, Toshiko Minamoto1, Kouji Iida1, Razia Sultana1, Noriyoshi Ishikawa2 and Satoru Kyo1

1 Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Japan

2 Department of Organ Pathology, Shimane University School of Medicine, Izumo, Japan

Correspondence to:

Kentaro Nakayama, email:

Keywords: microsatellite instability; endometrial cancer; immune checkpoint inhibitor; immunohistochemistry; mismatch repair protein; Immunology

Received: September 07, 2017 Accepted: October 28, 2017 Published: December 31, 2017


In recent years, it has become evident that tumor cells have immune escape mechanisms, and immune checkpoint inhibitor therapy (anti-PD-1/PD-L1 antibody) has shown benefit in various cancers. In endometrial tumors with microsatellite-instability (MSI), somatic mutations have the potential to encode ‘’non-self’’ immunogenic antigens, and lymphocytes have been shown to infiltrate the tumor. Therefore, immune checkpoint inhibitor therapy might be effective in endometrial cancers with MSI. Expression of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, and MSH6), the presence of tumor-infiltrating lymphocytes (CD8+), and PD-1/PD-L1 expression were assessed by immunohistochemistry in 149 patients with endometrial cancer. We examined whether tumors with MSI had an enhanced immune microenvironment and whether MSI could be a predictor of the therapeutic effect of PD-1/PD-L1 immunotherapy in endometrial cancer. Loss of MMR protein expression was identified in 42 (28.2%) of 149 patients (MSI group) with endometrial cancer. There was no significant relationship between MSI status and age (p = 0.193), histological grade (p = 0.097), FIGO stage (p = 0.508), pelvic lymph node metastasis (p = 0.139), or depth of myometrial invasion (p = 0.494). However, the presence of tumor-infiltrating lymphocytes (CD8+) and PD-L1/PD-1 expression were significantly higher in the MSI group compared to the microsatellite-stable group (p = 0.002, p = 0.001, and p = 0.008, respectively). These results suggest that immune checkpoint inhibitors (anti-PD-1/PD-L1 antibody) could be effective in endometrial cancers with MSI. The presence of MSI may be a biomarker for good response to PD-1/PD-L1 immunotherapy in endometrial cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23790